Clinical Study On Zhuyuxiaotan Decoction In Treating Interstitial Lung Disease Related To Connective Tissue Disease With Phlegm Stagnation In Lung

ObjectiveTo observe the clinical efficacy of Zhuyu Xiaotan Decoctionin the treatment of patients with connective tissue disease-related interstitial lung disease（CTD-ILD）of phlegm and blood stasis obstructing lung type and the influence of related laboratory indexes.Through the study of patients’clinical symptoms,laboratory indicators（ESR,CRP,IL-6）,mMRC dyspnea score,6-minute walking test and other aspects,to evaluate the safety of Zh uyu Xiaotan Yin therapy on CTD-ILD,explore its mechanism of action,deepen the understanding of CTD-ILD,and provide scientific theoretical basis for exploring the optimization scheme of TCM treatment of CTD-ILD.MethodsFrom November 2021 to January 2023,68 patients who were diagnosed as CTD-ILD phlegm and blood stasis obstructing lung type and met the inclusion criteria were collected from the Department of Pulmonary Disease and Rheumatology,Yantai Hospital of Traditional Chinese Medicine,Shandong Province.All cases signed informed consent with patients before entering the test.According to the ratio of 1:1,the random number table method was used to divide the patients into control group and observation group,34 cases in each group.The control group was given standardized indicators of western medicine,and the observation group was given Zhuyu Xiaotan Decoction on the basis of the control group for 4 weeks.The results of various in dicators before and after treatment were recorded.Finally,relevant statistical analysis was performed to evaluate the efficacy of Zhuyu Xiaotan Decoction on CTD-ILD phlegm and blood stasis obstructing lung type and related laboratory indicators,dyspnea score,6-minute walking test.Results1.General data analysis:Statistical analysis of the general data of the two groups of patients showed that there was no significant difference in gender,age,disease distribution and duration of onset between the observation group and the control group（P>0.05）.2.Efficacy index evaluation:（1）Chinese medicine syndrome scores:According to statistical analysis,there was no significant difference in symptom scores and scores between the two groups before treatment（P>0.05）.After treatment,the symptoms of the observation group were improved before and after treatment（P<0.05）.After treatment,the symptoms of expectoration,wheezing,chest pain,sleepiness and fatigue were improved in the control group,and the difference was statistically significant（P<0.05）.The improvement of cough,chest tightness and tongue image was not obvious,and the difference was not statistically significant（P>0.05）.After treatment,the observation group was superior to the control group in improving the symptoms of cough,expectoration,chest tightness,heavy body and fatigue,and the difference was statistically significant（P<0.05）.The main symptom score,secondary symptom score and total score of the observation group were improved,which were better than those of the control group,and the differences were statistically significant（P<0.05）.（2）Laboratory indicators:There was no significant difference in ESR,C RP and IL-6 between the two groups before treatment（P>0.05）.After treatment,the ESR,CRP and IL-6 in the observation group and the treatment group were significantly improved,and the difference was statistically significant（P<0.01）.After treatment,the improvement of ESR and CRP in the observation group was better than that in the control group,and the difference was statistically significant（P<0.05）.There was no significant difference in IL-6 between the two groups after treatment（P>0.05）.（3）mMRC dyspnea score:There was no significant difference in mMRC dyspnea score between the two groups before treatment（P>0.05）,which was comparable.After treatment,the mMRC dyspnea score of the observation group was significantly improved（P<0.001）,which was statistically significant;after treatment,the mMRC dyspnea score of the control group was improved（P<0.05）,which was statistically significant.After treatment,the improvement of the m MRC dyspnea score of the observation group was better than that of the control group（P<0.05）,which was statistically significant.（4）6MWT and SpO₂:There was no significant difference in 6MWT and Sp O₂between the two groups before treatment（P>0.05）.After treatment,6MWT and Sp O₂ were significantly improved in both groups（P<0.05）.（5）Overall efficacy:The total effective rate of the observation group was 87.5%,and the total effective rate of the control group was 71.86%.Th e curative effect of the observation group was better than that of the control group,with statistical significance（P<0.05）.（6）Safety analysis:There were no abnormalities in the safety indexes of the two groups after treatment.ConclusionZhuyuxiaotan Decoction combined with western medicine standardized treatment of CTD-ILD patients with phlegm and blood stasis obstructing lung type can improve patients’symptoms,laboratory indicators（ESR,CRP,IL-6）,m MRC dyspnea score,6-minute walking test and Sp O₂.The clinical efficacy is satisfactory,and the overall efficacy is better than that of the control group treated with western medicine alone.The oral safety of traditional Chinese medicine is high,and the clinical promotion value is high,which provides new ideas for clinical treatment.